Ratings COSMOS Pharmaceutical Corporation

Equities

3349

JP3298400007

Delayed Japan Exchange Other stock markets 10:30:00 2024-04-23 pm EDT			5-day change	1st Jan Change
14,385 ^JPY	-0.55%		+0.35%	-11.67%

Apr. 12	Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months	MT
Apr. 12	COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The company shows low valuation levels, with an enterprise value at 0.56 times its sales.
Over the last twelve months, the sales forecast has been frequently revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.
The company benefits from high valuations in earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
COSMOS PHARMACEUTICAL CORPORATION	-11.67%	3.64B		D+
SUNDRUG CO.,LTD.	-0.66%	3.34B		D-
TSURUHA HOLDINGS INC.	-23.58%	3.13B		D
SUGI HOLDINGS CO.,LTD.	+9.46%	2.79B		-
KUSURI NO AOKI HOLDINGS CO., LTD.	-10.21%	1.72B		-
CREATE SD HOLDINGS CO., LTD.	+9.79%	1.38B	-	-
GREAT TREE PHARMACY CO., LTD.	-18.60%	934M		-
SHUYU CIVILIAN PHARMACY CORP., LTD.	-40.53%	672M	-	-
FARMACIAS BENAVIDES, S.A.B. DE C.V.	-0.53%	451M	-	D+
CAWACHI LIMITED	-0.34%	383M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes